Abstracts

NEUTRALIZING AND T CELL RESPONSE AGAINST MPOX VIRUS AFTER MVA-BN VACCINE

Background: Modified vaccinia Ankara-Bavarian Nordik (MVA-BN) was licensed for Mpox. Recent data estimated single dose effectiveness around 78%, whereas its ability to induce neutralising antibodies (nAbs) has been measured as relatively low. Whether historical smallpox vaccination (HiSXV) or HIV infection may impact MVA-BN response remains to be determined. Methods: Blood samples collected from participants (pts)…

ENDOTHELIAL GM-CSF IN PLWH CONTRIBUTES TO PROINFLAMMATORY VASCULAR MICROENVIRONMENT

Background: People living with HIV (PLWH) show clinical and radiological findings of persistent endothelial dysfunction (ED), and twice-higher incidences of critical cardiovascular emergencies which is independent of other general risk factors. The effects of endothelium derived granulocyte macrophage colony stimulating factor (GM-CSF) on infiltrating immune cells that infiltrate the endothelium in PLWH are unknown, as…

GLYCOMIC BIOMARKERS OF BIOLOGICAL AGING ARE ALTERED DURING SUPPRESSED HIV INFECTION

Background: In the general population, host glycomic alterations – including loss of galactose (agalactosylation; measured as high levels of G-terminal ratio and G0 glycan groups) – on circulating IgGs drive inflammation and precede the onset of premature aging-associated diseases. However, the impact of antiretroviral therapy (ART)-suppressed HIV infection on these glycomic biomarkers of biological aging…

EARLY INFLAMMATORY PROFILES PREDICT MAXIMAL DISEASE SEVERITY IN COVID-19

Background: Better understanding of host inflammatory changes that precede development of severe COVID-19 could improve delivery of available antiviral and immunomodulatory therapies, and provide insights for the development of new therapies. Methods: In plasma from individuals with COVID-19, sampled ≤10 days from symptom onset from the All-Ireland Infectious Diseases Cohort study, we measured 61 biomarkers,…

TRAINED IMMUNITY FEATURES IN NK CELLS OF HIV-1 ELITE CONTROLLERS

Background: It is unclear how elite controllers (EC) spontaneously control HIV in the absence of antiretroviral therapy (ART). NK cells significantly contribute to antiviral innate immune responses and can display memory characteristics mirrored by high NKG2C expression. We aimed to investigate the phenotype of NK cells in ECs and their memory features, which favor antiviral…

ZINC ADJUVANT TREATMENT IN SARS-CoV-2: A RANDOMIZED CLINICAL TRIAL

Background: The immune system is highly susceptible to changes of zinc levels and this might imply a different response against infection. Prior evidence suggests some benefit on viral infection prognosis after zinc supplementation. We aim to study the efficacy of zinc supplementation in SARS-CoV-2 infection outcomes. Methods: This is an unicenter prospective, randomized cliinical trial…

LENACAPAVIR DISRUPTS HIV-1 CORE INTEGRITY WHILE STABILIZING THE CAPSID LATTICE

Background: Lenacapavir (LEN) is a potent HIV-1 capsid inhibitor (Gilead Sciences) currently in phase 2/3 clinical trials. Structural studies indicate that LEN binds two neighboring capsid subunits and stabilizes the cone-shaped capsid lattice, but its mechanism of viral inhibition and effect on capsids remain elusive. We recently utilized two different capsid-labeling approaches and demonstrated that…